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Lipid rafts are essential for release 
of phosphatidylserine-exposing 
extracellular vesicles from platelets
Hao Wei1, Jean-Daniel M. Malcor2 & Matthew T. Harper1
Platelets protect the vascular system during damage or inflammation, but platelet activation can result 
in pathological thrombosis. Activated platelets release a variety of extracellular vesicles (EVs). EVs 
shed from the plasma membrane often expose phosphatidylserine (PS). These EVs are pro-thrombotic 
and increased in number in many cardiovascular and metabolic diseases. The mechanisms by which 
PS-exposing EVs are shed from activated platelets are not well characterised. Cholesterol-rich lipid 
rafts provide a platform for coordinating signalling through receptors and Ca2+ channels in platelets. 
We show that cholesterol depletion with methyl-β-cyclodextrin or sequestration with filipin prevented 
the Ca2+-triggered release of PS-exposing EVs. Although calpain activity was required for release of 
PS-exposing, calpain-dependent cleavage of talin was not affected by cholesterol depletion. P2Y12 and 
TPα, receptors for ADP and thromboxane A2, respectively, have been reported to be in platelet lipid 
rafts. However, the P2Y12 antagonist, AR-C69931MX, or the cyclooxygenase inhibitor, aspirin, had no 
effect on A23187-induced release of PS-exposing EVs. Together, these data show that lipid rafts are 
required for release of PS-exposing EVs from platelets.
Platelets protect the vascular system during damage or inflammation, but inappropriate or excessive platelet 
activation results in pathological thrombosis1. Platelet activation and thrombosis on a ruptured atherosclerotic 
plaque in a coronary artery is the major precipitating event in acute coronary syndromes (ACS), such as unstable 
angina and myocardial infarction. Anti-platelet drugs are therefore used during ACS to prevent of further throm-
botic events2. These anti-platelet drugs include the cyclooxygenase inhibitor, aspirin, and P2Y12 antagonists, such 
as clopidorgel, prasugrel, ticagrelor or cangrelor2–4.
Activated platelets release a variety of extracellular vesicle (EVs). These have been variously categorised based 
on their size, surface markers, and mechanism of release. EVs that are shed from the plasma membrane have 
been variously called ‘microparticles’, ‘shedding microvesicles’ or ‘ectosomes’5. EVs shed from the plasma mem-
brane often expose phosphatidylserine (PS) on their outer leaflet. In non-activated platelets, PS is asymmetrically 
restricted to the inner leaflet. An increase in intracellular Ca2+ concentration ([Ca2+]i) during platelet activation 
can trigger loss of plasma membrane asymmetry and exposure of PS in the outer leaflet6. PS exposure may con-
tribute to shedding of EVs7. In contrast, vesicles formed by inward budding of intracellular granule membranes, 
and released by secretory granule exocytosis, have been termed ‘exosomes’8. Although exosomes are generally 
considered to not expose PS, a recent study suggests that exosomes might also expose PS9. However, since there 
has not been consistent use of these terms, we use the more neutral term, ‘extracellular vesicle’ (EV)5.
PS-exposing EVs are pro-thrombotic. PS forms a pro-coagulant binding site for the tenase and prothrom-
binase coagulation complexes. PS-exposing EVs increase the rate and extent of thrombin generation, pro-
moting thrombosis10. They also regulate wound healing, inflammation and vascular integrity11,12. Circulating 
PS-exposing EVs are elevated in many cardiovascular and metabolic disorders, including atherosclerosis, ACS, 
hypertension, heart failure, type II diabetes, and obesity13–22. In addition, platelet-derived EVs have been linked 
to tumour progression and metastasis23,24. These associations make PS-exposing EVs both attractive therapeutic 
targets and potential biomarkers of disease progression25.
The mechanisms by which PS-exposing EVs are shed from activated platelets are not well characterised. PS 
exposure and EV shedding can be triggered by an increase in [Ca2+]i26. EV shedding is inhibited in patients 
with Scott syndrome, who are deficient in ability to expose PS, indicating that PS exposure is an important part 
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of the molecular mechanism27. In addition, cytoskeletal disruption by the Ca2+-dependent protease, calpain, is 
required7,28,29. Beyond these events, little is known about how the process of shedding PS-exposing EVs from 
platelets is regulated.
Cholesterol-rich lipid rafts provide a platform for coordinating signalling in platelets and other cells30. Lipid 
rafts are involved in PS-exposing EV release from monocytes31, endothelial cells32 and erythrocytes33,34. In this 
study, we investigated whether lipid rafts are required for platelets to release PS-exposing EVs.
Results
The Ca2+ ionophore, A23187, triggers release of PS-positive platelet-derived EVs. Washed 
platelets were stimulated with the Ca2+ ionophore, A23187, to trigger release PS-exposing EVs. A Ca2+ ionophore 
was used rather than physiological agonists in order to bypass platelet receptors and Ca2+ entry channels, which 
may be affected by cholesterol depletion. Platelet-derived PS-exposing EVs were defined as CD41+/annexinV+ 
events that were smaller than 1 µm (Fig. 1). We acknowledge that the number of events seen by this approach is 
likely to be an underestimate of the total number of platelet-derived PS-exposing EVs as we will predominantly 
detect the largest microparticles. Platelets exposed PS and released PS-exposing EVs in response to increasing 
concentrations of A23187 (Fig. 1).
Depletion of platelet cholesterol prevents release of PS-positive EVs. To test whether lipid 
rafts are required for PS-positive EV release, cholesterol was depleted from washed platelets by treatment with 
methyl-β-cyclodextrin (MβCD). Following treatment with MBCD, platelets were fixed with PFA then stained 
with filipin, which binds to cholesterol with high affinity35. Filipin fluorescence decreased following treat-
ment with MβCD in a dose-dependent manner (Fig. 2a,b). In some previous studies, MβCD was incubated in 
platelet-rich plasma (PRP) to deplete cholesterol prior to isolation of washed platelets (e.g.36). However, in prelim-
inary studies we found no additional benefit of this approach in terms of cholesterol depletion, but also observed 
that it reduces platelet recovery after centrifugation from PRP, which may suggest an increase in mechanical 
fragility of the platelets. α-cyclodextrin (αCD), which does not remove cholesterol from membranes30, did not 
decrease filipin fluorescence, indicating the specificity of MβCD (Fig. 2a,b).
When platelets treated with MβCD (10 or 25 mM) were stimulated with A23187, no PS-exposing 
platelet-derived EVs were detected (Fig. 2c). In contrast, PS exposure in intact platelets (i.e. >1 µm) was unaf-
fected, suggesting that platelet activation and the exposure of negatively-charged phospholipids was not affected 
(Fig. 2d). Consistent with this, we did not observe an increase in annexinV negative EVs (CD41+, <1 µm) in 
MβCD-treated samples following A23187 stimulation (see representative density plots in Fig. 2e), indicating that 
the lack of PS-exposing EVs in these samples was not a result of inhibited PS exposure in the EVs themselves (and 
hence not detected as AnV+/CD41+ events). α-cyclodextrin (10 mM) had no effect on release of PS-exposing 
EVs or on platelet PS exposure (Fig. 2c,d). α -cyclodextrin has a similar structure to MβCD but has a much lower 
affinity for cholesterol. It can therefore be used as a control for any cholesterol-independent effects of MβCD. 
Representative density plots are shown in Fig. 2e. To confirm the flow cytometry data, the EVs were isolated by 
centrifugation and visualised by transmission electron microscopy (Fig. 2f). The inhibitory effect of MβCD was 
concentration-dependent, with less effect at 1–5 mM (Fig. 2g).
Figure 1. The Ca2+ ionophore, A23187, triggers release of PS-exposing EVs from platelets. Washed platelets 
were stimulated with the indicated concentration of A23187 for 10 minutes, after which samples were stained 
with anti-CD41-PerCP-Cy7, and annexin V-FITC to detect PS exposure. PerCP-Cy7 fluorescence was used to 
trigger acquisition of CD41+ events. The panels show density plots of events from low density (blue) to high 
density (red) of forward scatter (FSC-A) and FITC fluorescence. Unstimulated platelets have high FSC-A and 
low annexin V-FITC binding (LR). Stimulation with A23187 triggered PS exposure in platelets (UR) and release 
of PS-exposing EVs (UL). The vertical line separating left and right was defined by the FSC-A of 1 µm silica 
beads. The density plots are representative of data from 6 different donors.
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Figure 2. Cholesterol depletion inhibits release of PS-exposing EVs. (a) Platelets were treated with MβCD 
(10 mM or 25 mM), αCD (10 mM) or vehicle as control, then fixed and stained with filipin. Filipin fluorescence 
was determined by confocal microscopy. (n = 5; *p < 0.05; **p < 0.01; ns, not significantly different from 
control). (b) Representative images of filipin-stained platelets. (c) Following treatment with MβCD, MαCD or 
vehicle, platelets were stimulated with various concentrations of A23187 for 10 minutes. EVs were measured 
as in Fig. 1. (d) The percentage of platelets that stained positive for annexin V. (Mean ± SEM; n = 5). (e) The 
effect of different concentrations of MβCD on release of PS-exposing EVs in response to 10 µM A23187 
(Mean ± SEM; n = 5). (f) Representative density plots for platelets stimulated with 10 µM A23187.
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The effect of MβCD on plasma membrane integrity was assessed using a fluorescent fixable viability dye 
(FVD). This reagent is cell-impermeable so can be used to label cells that have lost plasma membrane integrity. 
Heat-killed platelets showed strong FVD fluorescence (Supplementary Fig. 1). In contrast, neither MβCD treat-
ment, nor stimulation with A23187 for 10 minutes, increased FVD fluorescence in platelets. The effect of MβCD 
on release of PS-exposing EVs is not due to platelet death. Consistent with this, re-plotting of the data in Fig. 2c,d 
to give PS-exposing EVs per platelet, or PS-exposing EVs per PS-exposing platelet (Supplementary Fig. 2), shows 
that the effect of MβCD on EV release is not due to reduced platelet viability or reduced platelet activation.
Although A23187 effectively stimulated EV release from platelets, it is possible that the mechanism of EV 
release in response to A23187 does not mimic the mechanisms by which EVs are released in response to phys-
iological platelet activators. To test this, platelets were stimulated with a mix of cross-linked collagen-related 
peptide (CRP-XL) and thrombin. This dual stimulation promotes PS exposure and release of PS-exposing EVs. 
Pre-treatment with MβCD (10 mM) inhibited release of PS-exposing EVs (Fig. 3a,b), but also inhibited PS expo-
sure in platelets (Fig. 3c), suggesting that platelet receptors or Ca2+ channels may also be affected by cholesterol 
depletion (see Discussion). For this reason, we continued with A23187 rather than more physiological activators.
Filipin, when applied to unfixed cells, can sequester cholesterol and disrupt lipid rafts. Platelets treated with 
filipin before stimulation with A23187 released significantly fewer detectable PS-exposing EVs (Fig. 4a; n = 5; 
**p < 0.01), without effect on PS exposure (Fig. 4b). In contrast, amphotericin B, a structurally-related poly-
ene macrolide antibiotic, had no effect on release of PS-exposing EVs over the same range of concentrations. 
Amphotericin B is selective for ergosterol over cholesterol37. Together, these data suggest that disruption of mem-
brane cholesterol prevents the release of PS-exposing EVs from platelets.
Cholera toxin B, a marker of lipid rafts, binds to platelet-derived EVs. Cholera toxin B (CTxB) 
binds to GM1 ganglioside, a widely-used marker of lipid rafts38. FITC-conjugated CTxB binds to unstimulated 
Figure 3. Cholesterol depletion inhibits release of PS-exposing EVs in response to physiological stimulation. 
Platelets were treated with MβCD (10 mM) or vehicle as control, then stimulated with CRP-XL (10 µg/ml) plus 
thrombin (1 U/ml). (a) EVs were measured as in Fig. 1. (b) The percentage of platelets that stained positive for 
annexin V. (Mean ± SEM; n = 5). (c,d) Representative density plots from these experiments.
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platelets (Fig. 5a). Following stimulation with A23187, the median fluorescence intensity of CTxB-FITC bound 
to intact platelets decreased (specific staining reduced to 78.4 ± 6.0% of matched controls; p < 0.05, n = 5; Fig. 5a). 
In addition, most platelet-derived EVs stained positive for CTxB-FITC (Fig. 5b). In this experiment, CTxB-FITC 
fluorescence was recorded through FL1, so annexin V-FITC was omitted. However, as shown in Fig. 1, almost all 
platelet-derived (CD41+) EVs that we could detect were annexin V positive. 74.7 ± 0.8% (n = 5) of CD41+ EVs 
detected stained positive for CTxB-FITC (indicated by gate in Fig. 5c). This suggests that GM1 is released from 
platelets in EVs and supports the hypothesis that EVs are released from sites of lipid rafts.
Cholesterol depletion does not affect calpain activity. Calpain, a Ca2+-dependent protease, is impor-
tant for release of PS-exposing EVs from platelets28,29. We confirmed this in our experimental system by treating 
platelets with calpeptin, a calpain inhibitor (140 μM), which significantly reduced the release of PS-exposing 
EVs (Fig. 6a). Calpeptin increased the proportion of platelets that bound annexin V at lower concentrations of 
A23187 (Fig. 6b), consistent with a previous report39. Stimulation with A23187 led to cleavage of talin, which was 
prevented by prior treatment with calpeptin (Fig. 6c), confirming that talin is a calpain substrate in platelets. In 
contrast, cholesterol depletion by MβCD had no effect on talin cleavage (Fig. 6d). This suggests that cholesterol 
depletion does not affect Ca2+-dependent activation of calpain in platelets.
P2Y12 and thromboxane signalling are not required for A23187-triggered release of 
PS-exposing EVs. The ADP receptor, P2Y12, and the thromboxane receptor, TPα, have been reported to 
reside in lipid rafts36,40,41. To determine whether disruption of either of these pathways could account for the effect 
of cholesterol depletion, platelets were treated with the P2Y12 antagonist, AR-C 69931MX (Cangrelor, 10 µM) or 
the cyclooxygenase inhibitor, aspirin (100 µM). Neither drug had any significant effect on platelet PS exposure or 
release of PS-exposing EVs (Fig. 7a–d).
Discussion
Platelet-derived PS-exposing EVs are pro-thrombotic, pro-inflammatory, and associated with cardiovascular and 
metabolic disease11. In this study we show that intact cholesterol-rich lipid rafts are required for platelets to release 
PS-exposing EVs. MβCD, which is widely used to disrupt lipid rafts, depleted cholesterol from platelets and pre-
vented the release of PS-exposing EVs from platelets. Filipin, which binds and sequesters membrane cholesterol, 
also prevented release of PS-exposing EVs. In contrast, the related polyene antibiotic, amphotericin B, had no 
effect. Cholera toxin B (CTxB) binds to the lipid raft marker, GM1 ganglioside. CTxB readily bound to platelet 
EVs, whereas CTxB binding of platelets was reduced by treatment with A23187, suggesting that GM1 ganglioside 
Figure 4. Filipin, but not amphotericin B, inhibits release of PS-exposing EVs. (a,b) Washed platelets were 
treated with the indicated concentrations of filipin or amphotericin B, or vehicle as control prior to stimulation 
with A23187 (10 µM). CD41+/annexin V+ EVs were identified as in Fig. 1. (a). EVs release in (a) are expressed 
as % of vehicle-treated, A23187-stimulated platelets (n = 5; **p < 0.01). (b) Shows the percentage of annexin 
V-positive platelets from these experiments.
www.nature.com/scientificreports/
6SCienTifiC RePoRTs |  (2018) 8:9987  | DOI:10.1038/s41598-018-28363-4
is lost from platelets during EV shedding. Together, these data indicate that lipid rafts have an essential role in the 
release of PS-exposing EVs from platelets.
The role of lipid rafts in formation and release of PS-exposing EVs is consistent with many other cell types. 
Erythrocytes treated with Ca2+ ionophores release PS-exposing EVs that are enriched in the lipid raft marker, 
stomatin33,34. Lipid rafts are required for monocytes to release tissue factor (TF)-rich EVs31. Lipid rafts also con-
trol the protein composition of these monocyte-derived EVs, by allowing incorporation of TF, PGSL-1 and β1 
integrins, but excluding CD4531,42. The role of lipid rafts is also consistent with the report that platelet-derived EVs 
are enriched in cholesterol relative to unstimulated platelets43.
The molecular mechanisms that control PS-exposing EV release in platelets are poorly understood, especially 
when considered in comparison to our detailed knowledge of other platelet effector processes, such as integrin 
αIIbβ3 activation or granule secretion44–47. A rise in [Ca2+]i leads to calpain activation and cleavage of cytoskeletal 
proteins, such as talin7,28,29. This may uncouple the plasma membrane from the cytoskeleton. In addition, the 
increased [Ca2+]i triggers exposure of PS in the outer leaflet of the plasma membrane through activation of the 
phospholipid scramblase, TMEM16F7. PS exposure appears to be important for EV release since PS-exposing EVs 
release is reduced in Scott Syndrome27, a rare bleeding disorder caused by mutations in TMEM16F48,49. Similarly, 
PS-exposing EVs release was reduced in Tmem16f−/− platelets50. PS exposure may promote EV release by altering 
membrane curvature51. However, beyond calpain and PS exposure, little is known about how platelets generate 
and release PS-exposing EVs.
How lipid rafts contribute to release of PS-exposing EVs is still unclear. Lipid raft disruption does not appear 
to disrupt PS exposure, since MβCD or filipin had no effect on annexin V binding to stimulated platelets. The loss 
of PS-exposing EVs is also not due to a selective deficit of PS exposure in EVs, since we do not see an increase 
in annexinV negative EVs following stimulation of MβCD-treated samples. In addition, lipid raft disruption 
does not appear to affect calpain activity, since calpain-dependent cleavage of talin was unaffected. Although 
Figure 5. Cholera toxin B (CTxB) binds to platelets and platelet-derived EVs. (a) Platelets, unstimulated (−) or 
treated with A23187 (+) were stained with FITC-conjugated CTxB then measured by flow cytometry. Median 
fluorescence intensity (MFI) in FL1 is shown for stained and unstained platelets. A23187 stimulation leads to a 
significant reduction in CTxB binding (n = 5; *p < 0.05). (b) MFI in FL1 for EVs in the same experiments.
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the receptors P2Y12 and TPα have been found in platelet lipid rafts, neither inhibition of P2Y12 nor inhibition 
of thromboxane synthesis with aspirin affected PS exposure or release of PS-exposing EVs. In contrast, previous 
reports have indicated a role for P2Y12 in the release of PS-exposing EVs when platelets are stimulated through 
cell surface receptors52,53. This implies that P2Y12 enhances signalling downstream of receptor stimulation, per-
haps by promoting intracellular Ca2+ signalling, rather than being involved in the EV release mechanism itself.
Lipid rafts may serve to localise the required molecular machinery for PS-exposing EV release but, beyond 
calpain and TMEM16F, this machinery is not known. One reason for this sparse information may be the relative 
difficulty in studying EVs. In this study, we have mostly used flow cytometry to demonstrate the presence of 
PS-exposing EVs. This is not without pitfalls. Extracellular vesicles (EVs) are believed to be heterogeneous pop-
ulation from 100 nm to 1 µm. Flow cytometry can struggle to resolve the smaller EVs5,54, and our measurement 
of PS-exposing EVs is likely to be an underestimate because we will predominantly be detecting the largest EVs. 
Platelet-derived EVs are also heterogeneous in their mechanism of formation, that is, whether they are derived 
from outward blebbing or budding from the plasma membrane (sometimes called microparticles, or ectosomes), 
Figure 6. Cholesterol depletion does not affect calpain activity. (a,b) Platelets were treated with the calpain 
inhibitor, calpeptin (140 µM) or the vehicle (DMSO) prior to stimulation with A23187. Number of PS-exposing 
EVs in (a) and percentage of platelet exposing PS is shown in (b) (n = 5). (c) Platelets were treated with 
calpeptin (or vehicle) then A23187, as indicate, then lysed. Proteins were separated by SDS-PAGE and talin 
detected with a specific antibody. The membrane was then stripped and re-probed with an anti-CD41-antibody. 
A23187-triggered talin cleavage was inhibited by calpeptin. The blots are representative of 5 independent 
experiments. (d) Platelets were treated as indicated with 10 mM MβCD (10β) 25 mM MβCD (25β), 10 mM αCD 
(10α), or vehicle as control (−), prior to stimulation where indicated. A23187-triggered talin cleavage was not 
affected by MβCD.
www.nature.com/scientificreports/
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or are formed by endocytosis into secretory granules and are released by subsequent exocytosis (sometimes called 
exosomes)5. The microparticles/ectosomes are thought to be the larger particles and more likely to expose PS, 
whereas the exosomes are thought to be smaller and not to expose PS8. In this study we are focusing on the larger, 
PS-exposing EVs, which are likely to represent the ectosome population. We cannot readily detect the smaller, 
endosome EVs in our flow cytometry experiments, and draw no conclusions either way regarding any potential 
role for lipid rafts in their release.
We have used the Ca2+ ionophore, A23187, to trigger PS-exposing EV release. This is not a physiological 
stimulus for platelets. However, we chose A23187 over more physiological activators such as thrombin or collagen 
for two reasons. First, PS-exposing EVs are released by PS-exposing platelets7,55. Not all platelets expose PS when 
physiological activators are used, even in combination56,57. In contrast, A23187 can induce PS exposure in the 
entire platelet population. Second, using a Ca2+ ionophore means that receptor activation and subsequent Ca2+ 
signalling mechanisms are bypassed. Disrupting lipid rafts may affect this signalling if physiological activators 
were used. Many platelet receptors are found in lipid rafts, including P2Y12 and TPα36,40,41. The major collagen 
receptor, GPVI, is recruited to lipid rafts on stimulation58 and lipid rafts regulate platelet activation by GPVI ago-
nists59. Important signalling proteins are localised in lipid rafts, such as type I protein kinase PKA60, and TRPC661, 
which is important for agonist-induced PS exposure57. Store-operated Ca2+ entry, another major pathway for 
Ca2+ entry leading to PS exposure62, is also dependent on intact lipid rafts63. We did observe that MβCD inhibited 
release of PS-exposing EVs in response to CRP-XL plus thrombin, which suggests that lipid rafts may also be 
important in this process in platelets stimulated with physiological activators. However, PS exposure in platelets 
was also significantly inhibited. The inhibition of release of PS-exposing EVs may reflect inhibition of PS expo-
sure, a process that is required for EV formation. TMEM16F itself does not appear to be affected by cholesterol 
depletion, since A23187-induced PS exposure was not affected by MβCD. Rather, cholesterol depletion is likely 
to affect the receptors, ion channels and signalling molecules required for triggering PS exposure in response to 
physiological activators.
In summary, we have demonstrated that cholesterol-rich lipid rafts are essential for Ca2+-triggered release of 
PS-exposing EVs from platelets. One potential future approach would be to compare the proteomes of platelet 
lipid rafts and of PS-exposing EVs to identify novel regulators of EV release.
Figure 7. P2Y12 and thromboxane signalling are not required for release of PS-exposing EVs. Platelets were 
treated with the P2Y12 antagonist, cangrelor (AR-C 69931MX, 10 µM; a,b) or the cyclooxygenase inhibitor, 
aspirin (100 µM; c,d) prior to stimulation with A23187. Release of PS-exposing EVs is shown in (a,c); PS 
exposure in platelets is shown in (b,d). Data are mean ± SEM (n = 5).
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Methods
Washed platelet preparation. Blood was drawn by venepuncture from healthy, drug-free volunteers, who 
had given written, informed consent in accordance with the Declaration of Helsinki. Use of human blood for 
these experiments was approved by the Human Biology Research Ethics Committee, University of Cambridge. 
Sodium citrate (3.8% v/v) was used as anticoagulant. Acid citrate dextrose (ACD; 85 mM tri-sodium citrate, 
71 mM citric acid, 111 mM D-glucose) was added (1:7 v/v) and platelet-rich plasma (PRP) separated by centrifu-
gation (200 g, 10 min, room temp., no brake). Prostaglandin E1 (100 nM) and apyrase (Grade VII; 0.02 U/ml) was 
added to PRP to prevent platelet activation during preparation. Platelets were pelleted from PRP by centrifuga-
tion (600 g, 10 min, room temp., with brake) and resuspended in HEPES-buffered saline (135 mM NaCl, 10 mM 
HEPES, pH 7.4.) as a density of 5 × 107 platelets/ml. Platelets were rested (30 °C, 30 min) prior to treatment with 
inhibitors or stimulation. CaCl2 (2 mM) was added immediately prior to simulation.
Flow cytometry. Platelets were treated with inhibitors as indicated in the Results section, followed by 
stimulation with A23187 (10 min). Samples were stained with FITC-conjugated annexin V-FITC (Abcam, 
Cambridge, U.K.), to detect exposed phosphatidylserine, and PE-Cy7-conjugated anti-CD41 antibody (eBiosci-
ence, ThermoFisher, U.K.), to distinguish platelet-derived events. Samples were analysed using a BD Accuri C6 
flow cytometer. PE-Cy7 fluorescence (FL3) was used to trigger event acquisition. PS-positive platelet-derived EVs 
were defined as CD41+/annexin V+ events that were smaller than 1 µm. The 1 µm gate was set in forward scatter 
(FSC) using 1 µm silica beads.
Confocal imaging. Platelets (1 × 108 /ml) treated with vehicle, MβCD or αCD were fixed with 1% para-
formaldehyde (PFA; Alfa Aesar), washed by centrifugation (1800 rpm, 10 minutes) resuspended in 250 μl 
phosphate-buffered saline then adhered to poly-L-Lysine-coated coverslips (0.01 mg/ml; overnight, 4 °C). After 
gentle washing, coverslip-attached platelets were stained with 50 μg/ml filipin in PBS with 33% (v/v) fetal calf 
serum (2 hours, room temperature). Coverslips were mounted onto glass plates using Fluoromount-G (0100-01, 
Southern Biotech). Images were taken using a Leica SP5 confocal microscope, objective 63 × oil, 405 nm excita-
tion and 411–505 nm emission. For quantitative analysis of filipin-stained platelets, images were obtained under 
identical conditions. Average intensity of fluorescence per platelet was measured using Fiji64.
Western blotting. Platelet lysates that contain 20 μg proteins were electrophoresed on 6% polyacrylamide 
gels for 45 minutes at 200 V. Proteins were transferred from gels onto 0.45μm polyvinylidene difluoride (PVDF) 
membranes (IPVH00010, Immobilon-P) for 1 hour at 100 V. Membranes were blocked with 5% w/v non-fat pow-
dered milk in Tris-buffered saline-Tween (TBS-T; 137 mM NaCl, 20 mM Tris, 0.1% Tween-20, pH 7.6) for 1 hour 
at room temperature, incubated overnight with agitation at 4 °C with 1:10,000 anti-talin antibody (clone 8D4; 
T3287, Sigma) or 1:5000 anti-CD41 antibody (ab134131, Abcam) and washed three times with TBS-T. To detect 
the primary antibody, membranes were incubated for 1 hour at room temperature with horseradish peroxidase 
(HRP)-conjugated anti-rabbit IgG (7074 S, Cell Signaling Technology) or anti-mouse IgG (7076 S, Cell Signaling 
Technology), again washed three times with TBS-T. To visualise the blot, membranes were exposed to Super 
Signal Chemiluminescent Substrate (34077, Thermo Scientific) for 5 minutes. The blots were exposed to X-ray 
films (Amersham Hyperfilm ECL, GE Healthcare) and developed using an OptiMax X-ray film processor (Protec 
Medizintechnik).
Transmission electron microscopy. Platelet suspensions were centrifuged to pellet platelets (600 g, 
10 minutes). EV-rich supernatants were absorbed onto glow-discharged carbon film-coated 400 mesh copper 
grids for 3 minutes, washed twice with distilled water, allowed to dry at room temperature, and negatively stained 
with 3% (w/v) uranyl acetate in water for 30 seconds. Imaging was performed using a Tecnai G2 transmission 
electron microscope at the Cambridge Advanced Imaging Centre.
Sources of materials. All reagents were obtained from Sigma (Poole, Dorset, U.K.) unless otherwise stated 
above. A23187 was from Acros Organics (Fisher Scientific, U.K.). Cangrelor (AR-C 69931MX) was from Selleck 
Chemicals (Stratech Scientific, Ely, U.K.). Cross-linked collagen-related peptide (CRP-XL) was synthesised by Dr 
Malcor according to previously published methods65.
Data analysis. Data are reported as mean +/− standard error of mean (SEM) from at least 5 independent 
platelet preparations, and compared using one-way or two-way analysis of variance (ANOVA), as appropriate, 
in GraphPad Prism v5. Concentration-response curves were fitted using a four-parameter logistical equation.
Data availability. The data are available from the corresponding author on reasonable request.
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